Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.45 |
| ▸ | ACVR1B | P36896 | 9/20 | 0.44 |
| ▸ | ACVRL1 | P37023 | 9/20 | 0.44 |
| ▸ | BUB1 | O43683 | 4/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14564464 | 0.94 | TGFBR1 (0.43) | TGFBR1ACVR1BACVRL1ACVR1NUDT1 | |
| SCHEMBL2212676 | 0.93 | NUDT1 (0.46) | TGFBR1ACVR1BACVRL1BUB1ACVR1 | |
| SCHEMBL12213373 | 0.86 | BUB1 (0.40) | TGFBR1ACVR1BACVRL1BUB1NUDT1 | |
| SCHEMBL14576083 | 0.85 | BUB1 (0.39) | TGFBR1ACVR1BACVRL1BUB1NUDT1 | |
| SCHEMBL12510856 | 0.80 | TGFBR1 (0.44) | TGFBR1ACVR1BACVRL1BUB1ACVR1 | |
| SCHEMBL14564463 | 0.79 | TGFBR1 (0.45) | TGFBR1ACVR1BACVRL1BUB1ACVR1 | |
| SCHEMBL14564461 | 0.79 | TGFBR1 (0.56) | TGFBR1ACVR1BACVRL1BUB1CSNK2A1 | |
| SCHEMBL2211654 | 0.79 | TGFBR1 (0.47) | TGFBR1ACVR1BACVRL1BUB1CSNK2A1 | |
| SCHEMBL2492437 | 0.77 | TGFBR1 (0.48) | TGFBR1ACVR1BACVRL1NUDT1 | |
| SCHEMBL8346247 | 0.74 | TGFBR1 (0.59) | TGFBR1ACVR1BACVRL1BUB1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066632-A1 | Fused bicyclic inhibitors of TGFbeta | SCIOS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066632-A1 | Fused bicyclic inhibitors of TGFbeta | SCIOS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066632-A1 | Fused bicyclic inhibitors of TGFbeta | TGFBR1, TGFB1, SMAD2 | TGFBR1 1/4885ACVR1B 11/4885ACVRL1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.